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Objectives. The aim of this study, a substudy of the Australia–
New Zealand trial of carvedilol in patients with heart failure due
to ischemic heart disease, was to determine the effects of this
treatment on left ventricular size and function with the use of
quantitative two-dimensional (2D) echocardiography.
Background. Beta-adrenergic blocking drugs have been shown
to improve left ventricular ejection fraction in patients with heart
failure due to either ischemic heart disease or idiopathic dilated
cardiomyopathy. However, the effects of such treatment on left
ventricular size remain uncertain.
Methods. One hundred twenty-three patients from 10 centers in
New Zealand and Australia participated in the 2D echocardio-
graphic substudy. Echocardiography was performed before ran-
domization and was repeated after 6 and 12 months of treatment.
Left ventricular end-diastolic and end-systolic volumes were mea-
sured from apical four- and two-chamber views with the use of a
modified Simpson’s rule method.
Results. After 12 months, heart rate was 8 beats/min lower in
the carvedilol than in the placebo group, whereas left ventricular
end-diastolic and end-systolic volumes were increased in the
placebo group but reduced in the carvedilol group. At 12 months,
left ventricular end-diastolic volume index was 14 ml/m2 less in
the carvedilol than in the placebo group (p 5 0.0015); left
ventricular end-systolic volume index was 15.3 ml/m2 less (p 5
0.0001), and left ventricular ejection fraction was 5.8% greater
(p 5 0.0015).
Conclusions. In patients with heart failure due to ischemic
heart disease, carvedilol therapy for 12 months reduced left
ventricular volumes, increased left ventricular ejection fraction
and prevented progressive left ventricular dilation. These changes
demonstrate a beneficial effect of carvedilol on left ventricular
remodeling in heart failure. The observed changes may explain in
part the improved clinical outcomes produced by treatment with
carvedilol.
(J Am Coll Cardiol 1997;29:1060–6)
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Myocardial infarction can lead to ventricular remodeling (1)
with compensatory dilation and hypertrophy and subsequent
systolic and diastolic dysfunction progressing to the clinical
syndrome of congestive heart failure. Activation of neurohor-
monal systems, including the renin-angiotensin-aldosterone
and sympathetic nervous systems, provides initial support for
the failing heart. However, the continued neurohormonal
activation in chronic heart failure (2) becomes deleterious with
excessive vasoconstriction, volume expansion and continued
deterioration in cardiac function. Ventricular remodeling can
be favorably altered by angiotensin-converting enzyme (ACE)
inhibitors (3), agents that have been shown to reduce morbid-
ity and mortality in patients with heart failure (4,5) and
asymptomatic left ventricular dysfunction (6).
The beta-adrenergic antagonists may provide further ben-
efit for patients with congestive heart failure through inhibition
of sympathetic activation. Several randomized clinical trials (7)
have shown that beta-blocker therapy improves left ventricular
ejection fraction after 3 to 6 months of treatment, whereas the
effects on symptoms and exercise tolerance have been variable.
A recent pooled analysis of the results from several trials
demonstrated an improvement in left ventricular ejection
fraction of ;5% (7). However, little is known about the effects
of such therapy on left ventricular size. Although beta-
blockade in normal subjects increases left ventricular ejection
fraction, the increase is due to an increase in left ventricular
volumes as a result of heart rate slowing rather than to any
intrinsic improvement in left ventricular function (8). Thus,
determination of the effect of beta-blocker therapy on left
ventricular size is important to help determine the mechanisms
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of the improvement in left ventricular ejection fraction that has
been reported. Left ventricular volumes are also powerful
predictors of survival after acute myocardial infarction (9,10),
more so than left ventricular ejection fraction. Thus, reduction
in left ventricular volumes with beta-blocker therapy is consis-
tent with such therapy improving clinical outcomes in patients
with congestive heart failure (11).
The Australia–New Zealand (ANZ) Heart Failure Re-
search Collaborative Group trial (12) of carvedilol in patients
with heart failure due to ischemic heart disease was conducted
primarily to determine the effect of such therapy on left
ventricular ejection fraction and exercise tolerance. The study
demonstrated that carvedilol, in addition to standard heart
failure therapy including ACE inhibitors, resulted in sustained
improvement in ejection fraction (assessed by radionuclide
ventriculography at 6 and 12 months). Exercise performance
was maintained despite a marked reduction in rate-pressure
product, and symptoms were unchanged at 12 months. Left
ventricular end-systolic dimension, assessed by M-mode echo-
cardiography, was significantly lower in the carvedilol group
than in the placebo group. However, the reduction in left
ventricular end-diastolic dimension was of borderline signifi-
cance (p 5 0.05). M-mode echocardiographic assessment of
the left ventricle assumes uniform or global abnormalities of
size and function (13). However, patients with heart failure
due to ischemic heart disease may have multiple regional wall
motion abnormalities; consequently, such measurements may
not provide the most accurate estimate of left ventricular size.
In these circumstances quantitative two-dimensional (2D)
echocardiography provides a more accurate assessment of left
ventricular size and shape. The present study, a substudy of the
ANZ carvedilol trial, was designed to evaluate the effects of
beta-blockade on left ventricular size and function by using 2D
echocardiography. In this report we examine the effects of
carvedilol treatment on left ventricular volumes.
Methods
Study design and subjects. The ANZ carvedilol trial was a
randomized, double-blind, placebo-controlled trial of beta-
blockade in patients with congestive heart failure. The details
of the treatment regimen and outcome assessments for the
main study have been described in full elsewhere (12). In brief,
the study involved 415 patients with heart failure due to
ischemic heart disease and was carried out in 20 hospitals in
New Zealand and Australia. Patients were randomized to
receive either carvedilol or matched placebo after a 2- to
3-week run-in period of open carvedilol therapy. After ran-
domization, the dosage of carvedilol or placebo was titrated up
to 25 mg twice daily, or the highest dose tolerated, during a
5-week period; maintenance treatment was then continued for
an average of 20 months. Main end point assessments, includ-
ing radionuclide left ventricular ejection fraction, treadmill
exercise, M-mode echocardiography and symptom assess-
ments, were performed at 6 and 12 months.
The present echocardiographic substudy was conducted at
10 centers (see Appendix) and involved 123 patients. Patients
were eligible for the trial if they had 1) chronic stable heart
failure due to ischemic heart disease (defined as a documented
history of myocardial infarction, an exercise electrocardiogram
positive for ischemia or angiographic evidence of coronary
artery disease); 2) left ventricular ejection fraction by radionu-
clide ventriculography ,45%; and 3) current New York Heart
Association (NYHA) functional class II or III or previous
NYHA functional class II to IV. In addition, eligibility for this
substudy required adequate echocardiographic images, which
included apical four- and two-chamber views suitable for left
ventricular volume analysis. These requirements were met by
123 patients (55%) from a total of 225 patients recruited at
these 10 centers. Exclusion criteria for the trial have been
outlined in detail elsewhere (12).
Echocardiographic methods. Two-dimensional echocardi-
ography was performed at the time of the baseline assessment
and at 6 and 12 months. The ultrasound machines used were
Acuson 128, Hewlett-Packard and Aloka (Aloka Co., Japan).
Echocardiograms were performed by experienced technicians
and repeated by the same technician within each center
wherever possible, with care to obtain similar serial images.
Images were recorded onto videotape at the end of the
expiratory phase of normal respiration. A standard protocol
was used based on apical four- and two-chamber views accord-
ing to the recommendations of the American Society of
Echocardiography (14).
All echocardiograms were analyzed at the central research
laboratory (University of Auckland) by one observer who had
no knowledge of treatment allocation. Cine loops of apical
four- and two-chamber views were digitized by using a dedi-
cated off-line computer (ImageVue, NovaMicrosonics) and
stored on optical disc. End-diastole was defined as the frame
with the largest and end-systole as the frame with the smallest
cavity area. Manual planimetry of the endocardial border was
performed and papillary muscles and intracavity thrombi (if
present) were included in the chamber area. Biplane end-
diastolic and end-systolic volumes were calculated by computer
software according to a modified Simpson’s rule (14) from the
areas determined by planimetry. Three cycles (or 10 in the
presence of atrial fibrillation) were measured for each assess-
ment, avoiding postectopic beats, and the average volumes
obtained. Primary end points were left ventricular end-
diastolic and end-systolic volumes. Secondary end points were
stroke volume and left ventricular ejection fraction. All vol-
umes were normalized to body surface area (m2) calculated
from the patient’s height and weight at each clinic visit. Stroke
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANZ 5 Australia-New Zealand
CI 5 confidence interval
NYHA 5 New York Heart Association
2D 5 two-dimensional
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volume was calculated as end-diastolic volume 2 end-systolic
volume. Ejection fraction was calculated as stroke volume/end-
diastolic volume.
Measurement reproducibility was assessed before analysis
of the study recordings by measuring left ventricular volumes
in 22 patients with heart failure and adequate echocardio-
graphic images who were screened for the main study but did
not meet the inclusion criteria. Each echocardiogram was
measured on two occasions .1 week apart. The coefficients of
variation for repeated measurements were 5.6% for end-
diastolic volume and 6.2% for end-systolic volume. Normal
ranges for left ventricular volumes have previously been estab-
lished in our laboratory (15): left ventricular end-diastolic
volume index 56.2 6 9.9 ml/m2 (mean 6 SD); left ventricular
end-systolic volume index 25.7 6 5.0 ml/m2; stroke volume
index 30.5 6 5.3 ml/m2; left ventricular ejection fraction 54.4% 6
3.4%).
Statistical analysis. Data were analyzed by using the sta-
tistical software package SAS (version 6.10) (16) according to
the original group allocation (i.e., by intention to treat).
Differences between the treatment groups at baseline were
tested by using the Student t test for continuous variables and
the chi-square test with continuity equation for categoric
variables. A multivariate approach to repeated measures
(MANOVA) was performed by using the general linear mod-
eling procedure of SAS, to allow correction for the correlation
of repeated observations over time. This procedure protects
against departures from type H covariance. The Helmert
transformation was used to compare repeated observations of
continuous echocardiographic variables. Post-hoc investiga-
tions were conducted by using orthogonal contrasts. Results
are presented as the F approximation in the Hotelling-Lawley
trace. All tests were two-tailed. A sample size of ;60 patients
in each treatment group was estimated to provide $80%
power at the 0.05 level of statistical significance to detect an
absolute change in left ventricular end-diastolic volume of 10
ml/m2 (assuming an SD for left ventricular end-diastolic vol-
ume index of 20 ml/m2). A 5% significance level was used
throughout.
Results
Study patients. Of the 123 patients, 63 were randomized to
carvedilol treatment and 60 to placebo. The study groups were
well matched at baseline (Table 1) and similar to other patients
in the main study. Mean baseline values 6 SD were 29.5 6
8.2% for left ventricular ejection fraction, 98 6 32.9 ml/m2 for
left ventricular end-diastolic volume index; and 71 6 30 ml/m2
for left ventricular end-systolic volume index. Seven patients
randomized to carvedilol and eight to placebo died before 1
year of follow-up. In addition, 13 patients in the carvedilol
group and 14 in the placebo group either had images that were
considered inadequate for analysis at 1 year or did not have an
echocardiogram performed. Consequently, the analysis of the
effect of carvedilol on left ventricular volumes comprised data
from 97 patients at 6 months (50 receiving carvedilol, 47
placebo) and 81 at 12 months (43 receiving carvedilol, 38
placebo).
Among the patients continuing to take study medication at
6 and 12 months, the mean dosages were similar in the two
groups: 43 mg daily at both 6 and 12 months in the carvedilol
group and the equivalent of 47 and 48 mg daily, respectively, in
the placebo group. Among those receiving either captopril
(n 5 77) or enalapril (n 5 24), there were no significant
changes in the dosages of these two ACE inhibitors between
baseline and 6 or 12 months. Among those receiving furo-
semide (n 5 90) there was a trend to a higher dose require-
ment in the placebo group and a lower dose requirement in the
carvedilol group at 12 months (85 and 94 mg daily at baseline
and 12 months, respectively, in the placebo group vs. 87 and
80 mg daily, respectively, in the carvedilol group, p 5 0.05 for
between-group comparison).
Heart rate and blood pressure. Heart rate was 8 beats/min
lower (95% confidence interval [CI], 3.7 to 12.3 beats/min) in
the carvedilol group than in the placebo group at 12 months.
At 6 months systolic blood pressure was reduced by 5.4 mm Hg
(95% CI, 211 to 0.3 mm Hg) between the two groups;
although this difference was of borderline significance, its
magnitude was similar to that of the highly significant differ-
ence observed in the main study with a larger number of
patients (5.6 mm Hg, p 5 0.001) (12).
Left ventricular volumes. In the carvedilol group, left
ventricular end-diastolic volume index was reduced (mean 6
SE) by 3.7 6 1.7 ml/m2 at 6 months of treatment and by 6 6 2.8
ml/m2 at 12 months (Table 2). Conversely, in the placebo











Previous MI 92% 93%
Medications
ACE inhibitor 86% 90%
Diuretic drug 71% 80%
Digoxin 40% 43%
Heart rate (beats/min) 75.6 6 11.7 78.1 6 11.2
Systolic BP (mm Hg) 129.5 6 16.8 131.6 6 16.7
Diastolic BP (mm Hg) 77.4 6 11.8 79.2 6 11.5
LV EDVI (ml/m2) 100.2 6 36 95.7 6 29
LV ESVI (ml/m2) 72.9 6 32 68.2 6 28
LV EF (%) 30.4 6 9.1 28.6 6 7.1
Sinus rhythm 90% 88%
Data are presented as mean value 6 SD or number or percent of patients.
Between-group comparisons of baseline variables were not significant. ACE 5
angiotensin-converting enzyme; BP 5 blood pressure; EDVI 5 end-diastolic
volume index; EF 5 ejection fraction; ESVI 5 end-systolic volume index; LV 5
left ventricular; MI 5 myocardial infarction; NYHA class 5 New York Heart
Association functional class.
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group this index increased by 4.4 6 2 ml/m2 and 8.1 6 3.1
ml/m2 at 6 and 12 months, respectively (Table 2). Overall, at 12
months, there was a difference of 14 ml/m2 (95% CI 222.5 to
25.9 ml/m2) in left ventricular end-diastolic volume index
between the carvedilol and placebo groups (Fig. 1).
Similar changes in left ventricular end-systolic volume index
were observed during follow-up (Table 2, Fig. 1). In the
carvedilol group left ventricular end-systolic volume index
(mean 6 SE) was reduced by 6.2 6 1.6 ml/m2 and 8.7 6 2.6
ml/m2 at 6 and 12 months, respectively. Conversely, in the
placebo group this index increased by 4 6 1.9 ml/m2 and 6.6 6
2.7 ml/m2 at 6 and 12 months, respectively. Overall, at 12
months, left ventricular end-systolic volume index was reduced
by 15.3 ml/m2 (95% CI, 222.7 to 27.9 ml/m2) between the
carvedilol and placebo groups (Fig. 1). Stroke volume index
was not significantly different between the two groups at 6 or
12 months (Table 2).
Left ventricular ejection fraction increased by 4.9% (95%
CI, 2.4% to 7.3%) in the carvedilol group compared with the
placebo group at 6 months, reflecting an increase from 28.6%
at baseline to 33.5% among patients assigned to carvedilol
(Table 2). These changes were maintained at 12 months (Fig.
2). Left ventricular ejection fraction remained unchanged in
the placebo group over the 12 months. A worst case imputed
analysis for left ventricular volumes and ejection fraction
(average values for the placebo group at 6 and 12 months were
imputed for missing data for both treatment groups) revealed
statistically significant results similar to those reported above
(treatment effects p 5 0.04, p 5 0.01 and p 5 0.002 for left
ventricular end-diastolic volume index, end-systolic volume
index and ejection fraction, respectively).
Discussion
This study demonstrated that 12 months of treatment with
the beta-blocker carvedilol reduced left ventricular volumes in
patients with heart failure due to ischemic heart disease. In
contrast, there was progressive left ventricular dilation in the
placebo-treated group. These changes occurred in patients
who were in clinically stable condition on entry to the study
and who, in the majority of instances, were already receiving
ACE inhibitor therapy. Thus, in addition to reducing left
ventricular volumes, carvedilol had a protective effect against
the progressive left ventricular remodeling occurring in these
patients. Whereas many studies have reported an increase in
left ventricular ejection fraction with beta-blocker therapy in









vs. 6 Months vs. 12 Months
Rest heart rate (beats/min)
Carvedilol 75.6 6 1.5 64.6 6 1.6 66.5 6 1.6
Placebo 78.1 6 1.5 74.6 6 1.5 76.5 6 1.6 0.0002 0.0007
Systolic BP (mm Hg)
Carvedilol 129.5 6 2.1 125.7 6 2.2 126.3 6 2.1
Placebo 131.6 6 2.2 132.5 6 2.6 132.5 6 2.5 0.04 0.2
Diastolic BP (mm Hg)
Carvedilol 77.4 6 1.5 75 6 1.3 74.5 6 1.3
Placebo 79.2 6 1.5 78.1 6 1.8 77.2 6 1.7 0.5 0.6
LV EDVI (ml/m2)
Carvedilol 100.2 6 4.6 95.9 6 4.6 95.6 6 4.9
Placebo 95.7 6 3.8 102.2 6 4.7 106.2 6 4.9 0.007 0.0015
LV ESVI (ml/m2)
Carvedilol 72.9 6 4.1 65.5 6 4.2 65 6 4.5
Placebo 68.2 6 3.6 73.8 6 4.4 76.4 6 4.5 0.0003 0.0001
SVI (ml/m2)
Carvedilol 27.2 6 0.9 30.4 6 .9 30.7 6 1.1
Placebo 27.5 6 0.9 28.4 6 1 29.8 6 1.2 0.2 0.4
LV EF (%)
Carvedilol 28.6 6 0.9 33.5 6 1.2 34.1 6 1.5
Placebo 30.4 6 1.2 29.3 6 1.2 29.2 6 1.3 0.0018 0.0015
*p values are from repeated measures multivariate analysis of variance (MANOVA) post hoc contrast tests for the
difference between carvedilol and placebo in the change from baseline to 6 and 12 months. Data are presented as mean
value 6 SE. SVI 5 stroke volume index; other abbreviations as in Table 1.
1063JACC Vol. 29, No. 5 DOUGHTY ET AL.
April 1997:1060–6 LEFT VENTRICULAR REMODELING WITH CARVEDILOL
patients with heart failure, the associated changes in left
ventricular size have not been reliably determined. One study
(17) demonstrated a significant reduction in end-diastolic
dimensions with the beta-blocker bucindolol compared with
placebo. However, in the subset of patients with ischemic heart
disease in that trial, ejection fraction did not increase despite
this apparent decrease in left ventricular size.
Clinical importance of reduction in left ventricular vol-
umes. Heart failure is a progressive disease, and the marked
neurohormonal activation that occurs in patients with heart
failure contributes to this progression (18). Progressive left
ventricular dilation may continue with no detectable changes
in left ventricular ejection fraction (19), an occurrence well
illustrated by the changes in left ventricular volumes in the
placebo group in the present study. Thus, when considering the
effect of an intervention on left ventricular ejection fraction as
a marker of left ventricular function, it is important to consider
the associated changes in left ventricular volumes.
Left ventricular volumes have been shown (9,10) to be the
most important predictors of survival after myocardial infarc-
tion. In the study by White et al. (10), end-systolic volume was
the most powerful predictor of survival and the addition of
end-diastolic volume or ejection fraction in a multivariate
model added no further prognostic power. Aside from the
prognostic value of left ventricular volumes, agents that can
reduce left ventricular size may also improve clinical outcomes.
The ACE inhibitor captopril attenuates left ventricular en-
largement after myocardial infarction (15) and improves sur-
vival in patients with left ventricular dysfunction after infarc-
tion (20). The main ANZ carvedilol trial (12) demonstrated a
26% reduction in a combined end point of death or hospital
admission after 20 months of treatment. In addition, clinical
studies from the United States (11) recently reported a large
reduction in mortality with carvedilol therapy in patients with
heart failure, although the number of events in these studies
was relatively small (53 deaths among 1,094 patients). The
beneficial effect of carvedilol on left ventricular remodeling
reported in the current study would be consistent with favor-
able effects of this agent on mortality.
Mechanism of improvement in left ventricular function.
Although the reduction in left ventricular volumes demon-
strated in the current study confirms that carvedilol has
beneficial effects on left ventricular function, the mechanism of
this improvement cannot be determined exactly because left
ventricular function was not assessed under standard loading
conditions. Carvedilol has both beta-blocking and alpha1-
blocking (vasodilating) effects (21). Although alpha1-
antagonists alone can potentially reduce left ventricular vol-
umes immediately by reducing preload and afterload, there is
evidence (22) of rapid development of tolerance to the effects
of such agents and some data (23) suggest that similar toler-
ance to the vasodilating effects of carvedilol may occur with
long-term administration.
When administered to normal subjects, beta-blockers in-
crease left ventricular ejection fraction but with accompanying
increases in both end-diastolic and end-systolic volumes (8).
Similarly, short-term beta-blockade in subjects with impaired
left ventricular function increases left ventricular volumes (24),
an action consistent with an acute negative inotropic effect.
However, the mechanisms of the reduction in left ventricular
volumes reported here with long-term beta-blocker use may be
Figure 1. Changes in left ventricular end-diastolic (LVEDVI) and
end-systolic (LVESVI) volume index from baseline (BL) to 6 months
(6M) and 12 months (12M). Data are presented as mean value 6 SE.
p values comparing carvedilol and placebo are for repeated measures
multivariate analysis of variance (MANOVA) over 12 months of
treatment.
Figure 2. Absolute change in left ventricular ejection fraction (LVEF)
from baseline to 6 and 12 months. Data are presented as mean value 6
SE. p values comparing carvedilol and placebo are for repeated
measures multivariate analysis of variance (MANOVA) over 12
months of treatment. Abbreviations as in Figure 1.
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quite different. Long-term slowing of heart rate alone, partic-
ularly where sympathetic activation and resultant tachycardia
have been prominent, may contribute to an eventual improve-
ment in intrinsic left ventricular function. Heart rate slowing
without such improvement would be expected to increase
rather than decrease left ventricular volumes. The improve-
ment in left ventricular ejection fraction with metoprolol
treatment in heart failure has been related (25) to the change
in heart rate with treatment but not to the baseline heart rate.
This suggests that patients with a wide range of baseline heart
rates at rest, not just those with very marked sympathetic
activation, may benefit from beta-blocker therapy. Although
the reduction in heart rate in the current study is undoubtedly
part of the mechanism of improvement in left ventricular
function, it is likely that other mechanisms are also contribu-
tory. Previous studies (26) using load-independent indexes
have suggested that long-term beta-blockade in heart failure
improves left ventricular contractility and mechanical work
without increasing myocardial oxygen consumption. Other
mechanisms may include beneficial effects on diastolic function
(26), direct protective effects against catecholamine excess on
myocytes (27), and improved regional wall motion. Hibernat-
ing myocardium may play an important role in the mechanism
of heart failure in patients with underlying ischemic heart
disease (28). In this situation improved left ventricular function
through favorable alterations in myocardial oxygen supply and
demand imbalance with beta-blockade may be relevant. Carve-
dilol has several unique properties that include potent antiox-
idant and anti-inflammatory effects (21). These properties are
not shared by other beta-blockers and may contribute to the
beneficial effects of this drug on left ventricular remodeling in
patients with heart failure.
Conclusions. Carvedilol therapy for 1 year in patients with
chronic heart failure due to ischemic heart disease reduces left
ventricular volumes, increases left ventricular ejection fraction
and protects against progressive left ventricular dilation. These
beneficial effects on left ventricular remodeling provide further
evidence of the benefit of beta-blockade in addition to stan-
dard treatment for heart failure, including ACE inhibitors. The
reduced volumes may mediate the beneficial effects of such
treatment on hospital admissions and survival at least in part
and provide a reliable surrogate for long-term outcomes in
patients with heart failure.
Appendix
Australia–New Zealand Heart Failure Research
Collaborative Group
Echocardiography substudy participating centers
Australia: Austin Hospital, Melbourne (H. Krum, Y. Murray, A. Tonkin,* A.
Trotter); Fremantle Hospital (R. Burton, J. Garrett, G. Lane,* J. Watts);
Princess Alexandra Hospital, Brisbane (C. Geddes, C. Hall, J. Stephensen, S.
Woodhouse*); Prince Henry Hospital, Sydney (T. Davidson, C. Hall, J. Turner,
W. Walsh*); Repatriation Hospital, Melbourne (J. Bradbury, A. Hamer,* L.
Hopkins, D. Jackson); Royal Brisbane Hospital, Brisbane (D. Cross,* F.
Moreland, C. Hall, B. Hawtin); Royal Hobart Hospital, Hobart (V. Kimber, M.
Saunders, A. Thomson*); Wesley Hospital, Brisbane (D. Colquhoun,* J. Gold-
smith, B. Hicks).
New Zealand: Auckland Hospital, Auckland (C. Bond, R.N. Doughty,*
S. Flett, J. Murphy, N. Sharpe,* G. Whalley); Tauranga Hospital, Tauranga
(J. Bruning, T. Jellyman, L. Nairn*).
Coordinating Centre
Clinical Trials Research Unit, Department of Medicine, University of
Auckland, Auckland, New Zealand (H. Bartram, C. Bond, R.N. Doughty,
G. Gamble, S. MacMahon,† A. McCulloch, A. Milne, J. Murphy, R. Prasad,
N. Sharpe†).
Central Echocardiography Laboratory, University of Auckland (R.N.
Doughty, G. Whalley).
*Principal Investigator. †Co-principal Investigator.
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